Objective: To examine the health-related quality of life (HRQoL) and factors associated with HRQoL in Chinese patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) using two generic preference-based HRQoL instruments, EQ-5D (plus EQ-VAS) and SF-6D, with the results compared with general population.
Method: CP/CPPS patients were recruited from two tertiary referral hospitals, and the general populations were randomly approached. After informed consent, subjects were interviewed using EQ-5D, EQ-VAS and SF-6D, and their socio-demographic and medical information was solicited.
Results: Compared to the general population (n = 364), CP/CPPS patients (n = 268) reported significantly worse HRQoL with median score of the EQ-5D utility index (0.73 vs. 0.85), SF-6D utility index (0.76 vs. 0.81), and EQ-VAS (70.0 vs. 85.0). Multiple linear regression analyses showed pain symptom had the strongest predictive power for HRQoL, compared to symptom duration and urinary symptom. Socio-demographic factors and comorbidities did not significantly contribute to poorer HRQoL.
Conclusion: CP/CPPS patients experienced deteriorated HRQoL with lower health-related utility scores compared to general population, and pain severity was the main physical symptom predicting decreased health-related utility. Further studies are needed to provide the reference utility index for the comparison and better characterizing the influence of geographic and cultural factors on variation of health-related utility of CP/CPPS patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11136-010-9697-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of extracorporeal shockwave therapy on chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled study.
Prostate Int
December 2024
Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Purpose: This study aimed to investigate the efficacy and safety of extracorporeal shock wave therapy (ESWT) over an 8-week period in individuals diagnosed with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) compared to a control group.
Materials And Methods: This prospective, double-blind, placebo-controlled study enrolled 46 participants diagnosed with CP/CPPS, who were randomly assigned to either the treatment group or the control group in a 2:1 ratio. In the treatment group, ESWT was administered at the perineum once a week for 8 weeks.
Effectiveness of Extended-Release Bupropion and Duloxetine on Pelvic Pain and Sexual Function among Patients with Chronic Prostatitis/Chronic Pelvic Pain.
Adv Biomed Res
October 2024
Department of Psychiatry, Psychosomatic Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: This study aimed to compare the efficacy of the two antidepressants, duloxetine and bupropion, on pelvic pain in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Materials And Methods: This single-blind clinical trial was conducted on 68 CP/CPPS patients. The patients with CP/CPPS received either an extended-release formulation of 150 mg/day bupropion (bupropion group) or duloxetine 30 mg/day for 12 weeks (duloxetine group).
NLRP3 inflammasome in expressed prostatic secretions as a potential biomarker of chronic prostatitis/chronic pelvic pain syndrome.
Adv Clin Exp Med
December 2024
Department of Urology, Tianjin Medical University Baodi Hospital, China.
Background: Pyroptosis has been implicated in the progression of chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS).
Objectives: The present study was performed to explore the diagnostic value of the levels of the pyroptosis-related protein nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 (NLRP3) inflammasome in the expressed prostatic secretions (EPS) of patients with CP.
Material And Methods: A total of 167 CP patients, including 85 National Institutes of Health (NIH)-IIIA CP patients and 82 NIH-IIIB CP patients, as well as 80 benign prostatic hyperplasia (BPH) patients and 80 healthy controls, were enrolled.
[How to help a patient with abacterial prostatitis?].
Urologiia
November 2024
FGBOU VO Novosibirsk State Medical University of Ministry of Health of Russia, Novosibirsk, Russia.
Introduction: Despite all the achievements of modern medicine, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) remains a difficult disorder to treat. Patients are often dissatisfied with the treatment outcomes, since the main symptoms, namely pain and urination disorders, usually decrease, but do not completely resolve.
Aim: To study the efficiency of the combined drug Prostatex Plus in the treatment of patients with CPPS (IIIb).
Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome.
Investig Clin Urol
November 2024
Department of Urology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Purpose: This study evaluated the effectiveness of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) treatments using multiple pharmaceutical agents that could simultaneously preserve or enhance fertility capability.
Materials And Methods: This was a single-center-based, randomized controlled study, whereas the final analysis evaluated a total 350 CP/CPPS patients (age range, 28-40 years) and 50 patients were randomly allocated to each therapeutic group, with a 1:1 ratio. The therapeutic groups consist of tadalafil (group 1, 5 mg daily), L-carnitine (group 2, 2 g daily), extract (group 3, 320 mg daily), group 4 (tadalafil+L-carnitine), group 5 (tadalafil+), group 6 (L-carnitine+), and group 7 (tadalafil+L-carnitine+).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!